Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 436 participants.
Also called NCT01551173
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 436 participants
- Sponsor
- Registry
-
NCT01551173
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01551173. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2014-06-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- Condition
- Lipid Metabolism Disorders
- Intervention (Drug)
- Fluvastatin sodium
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01551173- Content hash
62af8da1a0691b30550b05e79438e00206ea3b12dbf8d406a60295e890b278fe